New meta-analysis finds statistically significant evidence that vitamin C administration reduced length of ICU stays for surgery patients.
Photo © iStockphoto.com/spxChrome
A recently published meta-analysis1 evaluated how vitamin C effected the length of stay in the intensive care unit (ICU). Researchers identified 18 relevant studies with a total of 2004 patients, 13 of which investigated patients undergoing elective cardiac surgery. Results showed that in 12 trials with a total of 1766 patients, vitamin C reduced the length of ICU stay on average by 7.8%. In six trials, vitamin C administered orally at doses of 1-4 grams per day reduced length of stay by 8.6%. Additionally, in three trials in which patients needed ventilation for over 24 hours, vitamin C shortened the duration of mechanical ventilation by 18.2%.
The researchers explain that low vitamin C levels among hospitalized patients has been reported since the 1930’s, and vitamin C metabolism can change dramatically for patients undergoing severe physiological stress from infection or surgery. For example, they state that while 0.1 grams per day of vitamin C can maintain a normal blood plasma level in healthy people, doses of up to 4 grams per day might be necessary for critically ill patients.
“We consider that our finding is a proof of concept, strongly encouraging further research, rather than justifying recommendations for change in practice. In further studies, the dose-response relationship should be carefully investigated, and oral and intravenous administration should be compared directly,” the researchers conclude. “Vitamin C costs only pennies per gram, whereas one day in the ICU may cost thousands of dollars; therefore, an 8% decrease in ICU stay from the administration of 2 g/day of vitamin C warrants further research.”
1. Hemila H et al. “Vitamin C can shorten the length of stay in ICU: a meta-analysis.” Nutrients, vol. 11, no. 4 (2019): 708
Cracking the code: Advancements in calcium absorption and nutritional understanding
July 23rd 2024Recent research conducted by ILSI U.S. and Canada – a global, nonprofit federation dedicated to advancing precompetitive research in the food, nutrition and health realms – and partially funded by Balchem, has shed light on how to improve predictions of Ca bioavailability across different food matrices.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.